BidaskClub upgraded shares of GALAPAGOS NV/S (NASDAQ:GLPG) from a hold rating to a buy rating in a report published on Friday morning.
A number of other analysts have also issued reports on GLPG. Zacks Investment Research lowered GALAPAGOS NV/S from a strong-buy rating to a hold rating in a research note on Friday, January 4th. ValuEngine lowered GALAPAGOS NV/S from a strong-buy rating to a buy rating in a research note on Wednesday, January 2nd. Cantor Fitzgerald assumed coverage on GALAPAGOS NV/S in a research note on Wednesday, December 19th. They issued an overweight rating and a $130.00 price target on the stock. Credit Suisse Group raised GALAPAGOS NV/S from a neutral rating to an outperform rating in a research note on Thursday, December 13th. Finally, Raymond James began coverage on GALAPAGOS NV/S in a research report on Wednesday, November 14th. They set a strong-buy rating and a $157.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. GALAPAGOS NV/S presently has an average rating of Buy and an average price target of $122.00.
Shares of NASDAQ:GLPG opened at $104.45 on Friday. The company has a market capitalization of $5.41 billion, a PE ratio of -39.56 and a beta of 1.74. GALAPAGOS NV/S has a 1 year low of $85.00 and a 1 year high of $122.28.
GALAPAGOS NV/S (NASDAQ:GLPG) last issued its quarterly earnings results on Friday, October 26th. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.70. The firm had revenue of $119.99 million for the quarter, compared to analyst estimates of $82.15 million. GALAPAGOS NV/S had a negative return on equity of 7.66% and a negative net margin of 30.65%. Research analysts predict that GALAPAGOS NV/S will post -1.74 EPS for the current fiscal year.
Several hedge funds have recently bought and sold shares of the stock. Federated Investors Inc. PA raised its holdings in shares of GALAPAGOS NV/S by 17.8% in the 3rd quarter. Federated Investors Inc. PA now owns 1,677,922 shares of the biotechnology company’s stock valued at $188,648,000 after buying an additional 253,159 shares during the period. BlackRock Inc. raised its holdings in shares of GALAPAGOS NV/S by 18.4% in the 3rd quarter. BlackRock Inc. now owns 365,413 shares of the biotechnology company’s stock valued at $41,083,000 after buying an additional 56,848 shares during the period. Credit Suisse AG raised its holdings in shares of GALAPAGOS NV/S by 52.0% in the 3rd quarter. Credit Suisse AG now owns 190,376 shares of the biotechnology company’s stock valued at $21,404,000 after buying an additional 65,094 shares during the period. Jane Street Group LLC raised its holdings in shares of GALAPAGOS NV/S by 214.1% in the 3rd quarter. Jane Street Group LLC now owns 185,269 shares of the biotechnology company’s stock valued at $20,830,000 after buying an additional 126,277 shares during the period. Finally, Laurion Capital Management LP purchased a new stake in shares of GALAPAGOS NV/S in the 3rd quarter valued at $19,841,000. Hedge funds and other institutional investors own 18.13% of the company’s stock.
GALAPAGOS NV/S Company Profile
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
Further Reading: No Load Funds
Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.